GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » Net Change in Cash

AIM (AIM ImmunoTech) Net Change in Cash : $-14.35 Mil (TTM As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

AIM ImmunoTech's Net Change in Cash for the three months ended in Sep. 2024 was $-2.64 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $-14.35 Mil.

AIM ImmunoTech Net Change in Cash Historical Data

The historical data trend for AIM ImmunoTech's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Net Change in Cash Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.17 37.03 -6.41 -5.04 -21.61

AIM ImmunoTech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.77 -9.83 -2.14 0.26 -2.64

AIM ImmunoTech Net Change in Cash Calculation

AIM ImmunoTech's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-21.267+-0.832+0.485+0
=-21.61

AIM ImmunoTech's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-3.11+0.334+0.137+0
=-2.64

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech Net Change in Cash Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » Net Change in Cash
Comparable Companies
TRAW SNSE NLSP PMCB INTI OTLC NKGN LYRA JAGX HSTC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
0A4Y:UK HXB2:Germany
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
Website
https://www.aimimmuno.com
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Executives
Stewart Appelrouth director 2117 SW HIGHWAY 484, OCALA FL 34473
Thomas K. Equels director, officer: Vice Chairman of Board 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii director 2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ellen M Lintal officer: CFO 2117 SW HWY 484, OCALA FL 34473
William M Mitchell director 2117 SW HWY 484, OCALA FL 34473
Wayne S. Springate officer: VP of Operations 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
David R Strayer other: Medical Director 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale officer: CFO 600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli officer: VP, Quality Control 510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander officer: VP of Process/QualityAssurance 784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey officer: Senior Vice President 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii officer: CFO 23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence director 250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli officer: President & COO P.O. BOX 521, NEW VERNON NJ 07976